Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DOV Revamps Phase III Trial Population For Bicifadine

This article was originally published in The Pink Sheet Daily

Executive Summary

An NDA submission for the chronic lower back pain agent, expected in the first half of 2007, is postponed.

You may also be interested in...



DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck

DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.

DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck

DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.

DOV Stresses “Residual Value” Of Bicifadine In Chronic Pain Despite Initial Phase III Failure

Firm had planned an NDA filing in the first half of 2007 for use of the non-opioid analgesic for chronic low back pain.

Related Content

Topics

UsernamePublicRestriction

Register

PS064208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel